Treatment Options in Patients With R/R Multiple Myeloma in the Later-Line Setting
This roundtable series evaluates therapies for patients with relapsed/refractory multiple myeloma after they have recieved multiple types of treatment, as discussed by key opinion leaders and participants at virtual live events.
Single-Agent Talquetamab Stands Out in Later-Line Treatment of RRMM
October 5th 2023In the second article of a 2-part series, Amrita Krishnan, MD, looks at the overall landscape of treatment for patients with relapsed/refractory multiple myeloma and how the use of single-agent talquetamab stands out in comparison with other treatment options.
Talquetamab Shows High Response Rates in BCMA-Pretreated RRMM
November 29th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, discussed results of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.
Unanswered Questions on Sequencing Talquetamab for RRMM
December 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, and participants discussed their impressions of the efficacy and safety of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
